Anti-Avelumab Polyclonal Antibody (AV974024)

Name: Anti-Avelumab Polyclonal Antibody
Brand: abinScience
SKU: AV974024
Price: 168 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

50ug
100ug
1mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер

AV974024

Описание

Anti-Avelumab Polyclonal Antibody (AV974024) is a rabbit polyclonal antibody detecting Avelumab in ELISA.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.

Реактивность видов

General

Применения

ELISA

Хозяинский вид

Rabbit

Клоональность

Polyclonal

Изотип

IgG

Иммуноген

Avelumab

Цель

Rabbit polyclonal to Bavencio.

Специфичность

The product is specific for Avelumab. This antibody serves as an excellent positive control for Avelumab immunogenicity (ADA) assays.

Уровень эндотоксинов

Please contact with the lab for this information.

Чистота

>90% as determined by SDS-PAGE.

Очистка

Purified by antigen affinity column.

Номер доступа

CAS: 1537032-82-8

Форма

Liquid

Буфер хранения

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.

Информация об использовании продукта

Применение	Разбавление
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Устойчивость и хранение

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Фон

Avelumab with trade name Bavencio, is an FDA-approved drug to treat Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by Avelumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as

Примечание

For research use only.

Изображения

Ссылки

Даташит